scholarly journals Efficacy of direct‐acting antivirals: UK real‐world data from a well‐characterised predominantly cirrhotic HCV cohort

2019 ◽  
Vol 91 (11) ◽  
pp. 1979-1988 ◽  
Author(s):  
Lucia Macken ◽  
William Gelson ◽  
Matthew Priest ◽  
George Abouda ◽  
Stephen Barclay ◽  
...  
Keyword(s):  
Real World ◽  
Direct Acting Antivirals ◽  
Real World Data ◽  
World Data ◽  
Direct Acting

scholarly journals Public–Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals

2017 ◽  
Vol 153 (3) ◽  
pp. 626-631 ◽  
Author(s):  
Poonam Mishra ◽  
Jeffry Florian ◽  
Joy Peter ◽  
Monika Vainorius ◽  
Michael W. Fried ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Real World ◽  
Public Private Partnership ◽  
Direct Acting Antivirals ◽  
Real World Data ◽  
Private Partnership ◽  
World Data ◽  
Direct Acting

scholarly journals 4CPS-088 Direct-acting antivirals for the treatment of hepatitis c virus infection: a real-world data analysis

2018 ◽  
Author(s):  
A Garcia Sacristan ◽  
JM Martínez-Sesmero ◽  
H Quirós Ambel ◽  
FJ Manzano Lista ◽  
A Dominguez Barahona ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Data Analysis ◽  
Hepatitis C ◽  
Virus Infection ◽  
Real World ◽  
Hepatitis C Virus Infection ◽  
Direct Acting Antivirals ◽  
Real World Data ◽  
World Data ◽  
Direct Acting

scholarly journals Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection in Taiwan

2021 ◽  
Author(s):  
Kao-Chi Chang ◽  
Shui-Yi Tung ◽  
Kuo-Liang Wei ◽  
Chen-Heng Shen ◽  
Yung-Yu Hsieh ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Real World ◽  
Large Scale ◽  
Population Analysis ◽  
Chang Gung Memorial Hospital ◽  
Efficacy And Safety ◽  
Direct Acting Antivirals ◽  
Real World Data ◽  
Direct Acting

Abstract Background/Purpose of StudyClinical trials have demonstrated excellent efficacy and safety of pangenotypic direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV). However, there are limited large-scale real-world data on these pangenotypic DAAs. This study examined the results of two pangenotypic regimens, glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvir (SOF/VEL), in a real-world setting in Taiwan.MethodsAll HCV patients treated with GLE/PIB or SOF/VEL from August 2018 to April 2020 at the Chiayi Chang Gung Memorial Hospital were included. The primary end point was sustained virologic response 12 weeks after treatment cessation (SVR12). Adverse events (AEs) were also reported.ResultsA total of 1 356 HCV patients received pangenotypic DAA treatment during the study period: 742 patients received GLE/PIB and 614 received SOF/VEL. The rates of SVR12 for GLE/PIB and SOF/VEL were 710/718 (98.9%) and 581/584 (99.5%), respectively, by per-protocol analysis, and 710/742 (95.7%) and 581/614 (94.6%), respectively, by evaluable population analysis. Eleven patients (GLE/PIB: 8, SOF/VEL: 3) did not achieve SVR12. The most common AEs for GLE/PIB and SOF/VEL were pruritus (17.4% vs. 2.9%), abdominal discomfort (5.8% vs. 4.4 %), dizziness (4.2% vs. 2%), and malaise (3.1% vs. 2.9%). Laboratory abnormalities were uncommon, with <1% of patients exhibiting elevated total bilirubin or aminotransferase levels with both regimens. There were five drug discontinuations owing to AEs (bilirubin elevation: 3, dermatological issues: 2).ConclusionIn real-world practice, the pangenotypic DAAs GLE/PIB and SOF/VEL are effective and well tolerated, achieving high SVR12 rates for patients with all HCV genotypes.

Real-world data on direct-acting oral anticoagulants

2018 ◽  
Vol 150 (4) ◽  
pp. 161
Author(s):  
Luis Rodríguez-Padial ◽  
Miguel Ángel Arias ◽  
Francisco Martín Rodríguez
Keyword(s):  
Real World ◽  
Oral Anticoagulants ◽  
Real World Data ◽  
World Data ◽  
Direct Acting ◽  
Direct Acting Oral Anticoagulants
Sign in / Sign up

Export Citation Format

Share Document